SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

PIRAMAL PHARMA

BSE: 543635 28 Jun 2025
Healthcare
₹ 194.3
PIRAMAL PHARMA LIMITED specializes in Pharmaceuticals within the Healthcare sector.

PIRAMAL PHARMA - Share Price & Details

Market Cap
₹25,934
High /Low
308.0 / 145.0
Stock P/E
285.0
Book Value
₹61.3
Dividend Yield
0.07
ROCE
6.53
ROE
₹1.14
Face Value
10.0
PEG Ratio
NA
EVEBITDA
₹18.3
Debt
4,856
CMP / FCF
1,177
Debt to equity
₹0.6
NP Ann
91.1
High price all time
308.0
Piotroski score
₹8.0
Graham Number
30.8
No. Eq. Shares
133.0
Net CF
₹-26.0
Net profit
91.1
Price to book value
3.18
Interest Coverage
₹1.98
Low price all time
61.6
Industry PE
32.0
Reserves
₹6,801
Free Cash Flow
₹233

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
PIRAMAL PHARMA LIMITED17293.12772.716898.02.0925,934285.0
PFIZER LTD.6364.93309.45919.172.3425548167.0
Syngene International Limited9668.01744.09484.04.332543453.9

Peer Comparison Chart


About PIRAMAL PHARMA

PIRAMAL PHARMA LIMITED, with Security Code 543635, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Piramal Pharma Expands Biologics Manufacturing Infrastructure to Support End-to-End Drug Development

(12 Jun 2025)
Piramal Pharma Limited is addressing the increasing demand for integrated biologics manufacturing by enhancing its capabilities and expertise in drug...
Read more →

Piramal Pharma Sees Significant Rise in Open Interest Amid Increased Trading Activity

(10 Jun 2025)
Piramal Pharma Ltd has seen a significant rise in open interest, reaching 5,219 contracts, alongside a trading volume of 2,888 contracts.
Read more →

Piramal Pharma shares gain after Canada unit gets zero observations from USFDA with no action indicated

(05 Jun 2025)
Shares of Piramal Pharma Ltd. gained on Monday, June 2, after the company said the US Food and Drug Administration had issued a form 483...
Read more →

Piramal Pharma's Canada facility gets zero USFDA observation

(05 Jun 2025)
Piramal Pharma announced that the United States Food and Drug Administration (USFDA) has completed a general good manufacturing practices...
Read more →

From Discovery to Delivery: How Piramal Pharma Limited is Strengthening its Drug Development Capabilities

(29 May 2025)
Peter DeYoung, CEO at Piramal Pharma Limited, explains how Piramal is meeting the growing demand for integrated biologics manufacturing by...
Read more →

Piramal Pharma promotes Women’s Health with i-pill Daily Campaign

(24 May 2025)
Piramal Consumer Healthcare launched its new campaign for i-pill Daily, reinforcing its commitment to women's health, dignity, and informed...
Read more →